

<b>Info Sheet for Technical description</b>
---

No. XXXX (事務局付番)

**Organization**

\* Mandatoty fields

Name of Organization*	CellSeed Inc.	
Address, City, States, Zip, Country*	15F(East Wing)Telecom Center Building 2-5-10, Aomi, Koto-ku, Tokyo 135-0064 Japan	
URL	<a href="https://www.cellseed.com/en/">https://www.cellseed.com/en/</a>	
Brief Descriptions of Organization* (Approx. 100 words)	CellSeed Inc. was founded in 2001 (JASDAQ listed in 2010) to commercialize a world-first technology of "Cell Sheet Engineering" based on temperature responsive polymer. By using this technology, CellSeed have developed a variety of intelligent cell cultureware which are used by many researchers aggressively to conduct R&D activities world widely. In Japan, there are 3 regenerative medicines approved by PMDA which are using our cell sheet engineering technology. CellSeed have two pipelines of Esophageal cell sheet (in Phase 3) and Allogeneic chondrocyte cell sheet (submitting CTN for Phase 3) as well. Besides, CellSeed have in-house CPC which could manufacture cell products for clinical use, not only for our clinical trial but also providing CDMO service to domestic and abroad users.	
Contact address	Name*	Yuji Ueno
	Department* / Position	Business Development Department/Director
	E-mail* / TEL	<a href="mailto:yuji.ueno@cellseed.com">yuji.ueno@cellseed.com</a>

**What kind of technology do you want to offer? \***

- A.** Clinical Development Pipelines → Please see **Sheet [A]**
- B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- C.** Platform Technologies(\*) that are not included in the above (Group B) → Please see **Sheet [C]**
- \* Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

**If you agree to the following, please check "Yes" below. \***

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- Yes

**Do you have any collaborations/partnerships with pharmaceutical companies?**

- Yes
- No

**If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?**

- Angel / Seed (including AMED/JST grants)
- Series A
- Series B
- Series C
- Series D or further advanced stages

**Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? \***

Options*	Comments
<input checked="" type="checkbox"/> Yes	Please kindly inform us when the presentation materials are provided to a third party through FIRM.
<input type="checkbox"/> No	

Filled in by\*

Date\*

	Dandan Song
	2023.09.15

**Sheet [B]** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc.**Info Sheet for Technical overview**

No. XXXX (事務局付番)

\* Mandatoty fields

**Title\***CDMO**Category\***

- |  |  |   |
|--|--|---|
| <input checked="" type="checkbox"/> Facilities                                   | <input type="checkbox"/> Manufacturing equipment | <input type="checkbox"/> Inspection equipment |
| <input type="checkbox"/> Cells   | <input type="checkbox"/> Culture medium          | <input type="checkbox"/> Reagents             |
| <input type="checkbox"/> Cell banking  | <input type="checkbox"/> Storage / Container     | <input type="checkbox"/> Logistics            |
| <input checked="" type="checkbox"/> Cell / Viral vector manufacturing technology |  |   |

**Description\***

CellSeed has an in-house CPC space of about 763 m<sup>2</sup>, which is approved by MHLW (Ministry of Health, Labor, and Welfare) and PMDA (Pharmaceuticals and Medical Devices Agency), and certified by ISO. We have extensive experience in various kinds of cell sheet production, such as autologous chondrocyte cell sheet, esophageal cell sheet, periodontal ligament cell sheet, mesenchymal stem cell-induced liver cell sheet, and others. These cell sheet products are utilized in Advanced Medical Care B treatments or clinical trials, among other applications. For all cell sheet production, we utilize our innovative cell sheet engineering technology, which employs temperature-responsive polymers.

For autologous chondrocyte cell sheet, cells are isolated from the patient's own cartilage, and for allogeneic chondrocyte cell sheet, cells are extracted from polydactyly tissue. Now we have established an allogeneic chondrocyte cell bank for clinical use and are preparing for Phase 3 clinical trials of an allogeneic chondrocyte cell sheet for the treatment of knee osteoarthritis in Japan.

Cell sheet technology is an excellent option for regenerative medicine due to its advantages such as cell-only formation, ease of transplantation by placing it in the defect area without suturing, and high engraftment capacity. We offer top-notch services for cell sheet production, including preliminary development and commercial manufacturing. However, our CDMO business is not limited solely to cell sheet products. We can offer customized services to help expand your cell products in the Japanese market, leveraging our vast experience in cell culture and sheet production. Additionally, we can provide support for regulatory affairs, including PMDA consultation, as needed.

Don't hesitate to contact with us and we are ready to support your business in Japan!

**Filled in by\***

Dandan Song

**Date\***

2023.09.15